Free Trial
→ The End of Elon Musk…? (From Brownstone Research) (Ad)tc pixel

PureTech Health (LON:PRTC) Stock Price Up 14.2% - Still a Buy?

Written by MarketBeat
Updated September 22, 2025
PureTech Health logo with Medical background

Key Points

  • PureTech Health's shares rose 14.2% during mid-day trading, reaching a high of GBX 123.80 ($1.67) and significantly increasing trading volume to over 9 million shares, up 1,053% from average levels.
  • The company has a market capitalization of £293.65 million and noteworthy financial ratios, including a price-to-earnings ratio of 714.71.
  • Insider Bharatt Chowrira purchased 167,739 shares at an average price of GBX 1 per share, indicating confidence in the company, as insiders own 13.13% of the stock.
  • Five stocks to consider instead of PureTech Health.

PureTech Health plc (LON:PRTC - Get Free Report)'s share price was up 14.2% during trading on Saturday . The company traded as high as GBX 123.80 ($1.67) and last traded at GBX 121.50 ($1.64). Approximately 9,013,305 shares changed hands during mid-day trading, an increase of 1,053% from the average daily volume of 781,543 shares. The stock had previously closed at GBX 106.40 ($1.44).

PureTech Health Stock Up 4.2%

The company has a current ratio of 3.68, a quick ratio of 2.51 and a debt-to-equity ratio of 45.82. The firm has a market capitalization of £303.07 million, a price-to-earnings ratio of 737.65 and a beta of 1.02. The firm has a 50 day moving average price of GBX 129.31 and a two-hundred day moving average price of GBX 129.65.

Insider Buying and Selling

In related news, insider Bharatt Chowrira acquired 167,739 shares of PureTech Health stock in a transaction on Thursday, July 3rd. The shares were bought at an average price of GBX 1 per share, for a total transaction of £1,677.39. 13.13% of the stock is owned by company insiders.

About PureTech Health

(Get Free Report)

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.

Read More

Should You Invest $1,000 in PureTech Health Right Now?

Before you consider PureTech Health, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PureTech Health wasn't on the list.

While PureTech Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

5G Stocks: The Path Forward is Profitable Cover
5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report
Like this article? Share it with a colleague.